Addex Therapeutics (APE) Spin-Out Raises $105M; Addex Holds 8.5% Stake Valued at $18.6M
Addex Therapeutics' spin-out, Neurosterix, raised $105M in Series B funding. Addex holds an 8.5% stake valued at $18.6M. Funds will support Phase 2 development of NTX-253, following completed Phase 1 studies.
How this was made
The 30-second read
Why it matters
The capital raise provides runway for Neurosterix's Phase 2 development and may lift Addex's stock as investors price in the new valuation.
Market read
A material financing event for a mid‑cap biotech, likely to affect Addex's share price and sector sentiment.
What to watch
Success of Neurosterix's Phase 2 trial is uncertain; the financing does not guarantee positive outcomes.
Background
Addex Therapeutics (APE) announced a spin‑out, Neurosterix, which completed a $105M Series B round. Addex did not participate but its 8.5% stake is now valued at $18.6M.
Market effects
May improve sentiment for biotech spin‑outs and related clinical‑stage companies.
US biotech sector could see modest uplift.
Limited to investors tracking Addex and similar biotech pipelines.
Counterpoint
The raise could dilute existing shareholders if additional equity is issued in the future.
Key entities
- companyAddex Therapeutics
Parent biotech company, ticker APE.
- companyNeurosterix
Spin‑out of Addex focused on NTX-253.
